Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA
Glenmark’s Ryaltris nasal spray, using Aptar Pharma’s VP3 nasal spray system, treats nasal and ocular symptoms.
Stay updated with breaking news from Aptar Pharma Services. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Glenmark’s Ryaltris nasal spray, using Aptar Pharma’s VP3 nasal spray system, treats nasal and ocular symptoms.
Glenmark’s Ryaltris nasal spray, using Aptar Pharma’s VP3 nasal spray system, treats nasal and ocular symptoms.
New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma’s VP3 Nasal Spray SystemCrystal Lake, Illinois, January 27, 2022 - Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, today announced that its VP3 multido...
ORLANDO, Fla. (PRWEB) June 10, 2021 -- In direct response to the rapid growth of the recently launched Human Factors + (HF+) program, Noble, an Aptar Pharma
Noble Launches Human Factors Engineering Services to Support Product Development and FDA Approval of Med Devices and Combination Products Human Factors Plus (HF+) is an extension of the company's understanding of the patient experience when it comes to self-administering drug therapies. This content was submitted directly to this website by the supplier. Feb 3rd, 2021 Noble, an Aptar Pharma company and provider of drug delivery training device programs for pharmaceutical companies and original equipment manufacturers, announced the launch of Human Factors Plus (HF+), an expanded service to fu...